© 2017 Pharmstandard Ventures
Pharmstandard Ventures is a Venture Arm within Pharmstandard, JSC, Russia's leading pharmaceutical company. We were formed in 2013 as Inbio Ventures, and changed our name to Pharmstandard Ventures after corporate restructuring in 2017
LATEST NEWS
TearSolutions, Inc. Secures $3M Series B Funding
Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
Pharmstandard Ventures is looking for innovative drug discovery/development projects targeting the unmet medical needs or providing dramatic advantages over the competition globally